Developing treatments for enteroviruses affecting children
THERAPEUTICS FOR EMERGING HUMAN ENTEROVIRUSES
['FUNDING_OTHER'] · HDT BIO CORPORATION · NIH-10684970
This study is working on developing special antibodies to help fight off enteroviruses like EV-D68, which can make young children very sick, and aims to create new treatments since there aren’t any available right now.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | HDT BIO CORPORATION (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-10684970 on ClinicalTrials.gov |
What this research studies
This research focuses on creating monoclonal antibodies to combat enteroviruses, particularly EV-D68, which can cause severe respiratory and neurological issues in young children. The project aims to develop effective therapeutics since there are currently no available treatments or vaccines for this virus. By targeting the enterovirus family, the research seeks to provide a broad-spectrum solution that could help protect vulnerable pediatric populations from serious health complications. The approach involves advanced antibody development techniques to ensure efficacy against these pathogens.
Who could benefit from this research
Good fit: Ideal candidates for this research are children aged 0-11 years who are at risk of or suffering from enterovirus infections.
Not a fit: Patients who are older than 21 years or those not affected by enterovirus infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to effective treatments for enterovirus infections, significantly improving health outcomes for affected children.
How similar studies have performed: Other research has shown promise in developing monoclonal antibodies for viral infections, indicating potential success for this approach.
Where this research is happening
SEATTLE, UNITED STATES
- HDT BIO CORPORATION — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SAR, KANDYMA — HDT BIO CORPORATION
- Study coordinator: SAR, KANDYMA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Nervous System Diseases, Neurologic Disorders, Neurological Disorders